Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 16, 2008. The report details a specific corporate action regarding the company's share buyback program authorized by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share repurchases.
- Shares Purchased: 2,985,000 Ordinary shares.
- Purchase Price: 1,179.689 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.02% of total voting rights).
- Shares in Issue: 5,255,662,034 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,985,000 shares purchased on July 16, 2008. Consequently, the number of shares held in Treasury increased to 474,194,158, while the number of shares in issue stands at 5,255,662,034.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance notification confirming the execution of a share buyback in accordance with shareholder authority and the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total cost of the buyback transaction (2,985,000 shares at 1,179.689 pence).
- Confirm the updated total voting rights denominator (5,255,662,034 shares) for disclosure threshold calculations.
- Note that the purchased shares were cancelled, not held indefinitely as treasury stock without cancellation.
- Check subsequent filings for the impact of this buyback on earnings per share (EPS) and return on equity (ROE).